Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 70518-2107

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 70518-2107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Venlafaxine Hydrochloride 75 mg extended-release capsules in a package of 30. The label shows the product name, strength, dosage form, and quantity. It indicates repackaging by RemedyRepack Inc. and manufacturing by Aurobindo, India. Includes NDC 70518-2107-00, storage instructions, and a QR code.*

FDA Label Image

Venlafaxine HCl 75mg 70518 2107 01

Venlafaxine Hydrochloride 75 mg extended-release oral capsules label showing quantity 30 and repackaged by RemedyRepack Inc. The label includes the NDC number 70518-2107-01, manufacturer Aurobindo, and storage instructions. The label specifies "RX ONLY" and instructs to see package insert for directions.*

FDA Label Image

Venlafaxine HCl 75mg 70518 2107 02

Venlafaxine Hydrochloride 75 mg extended-release capsules packaging label. The label shows a quantity of 90 capsules. Manufactured by Aurobindo in India, repackaged by RemedyRepack Inc., Indiana, PA. The label includes NDC numbers, storage instructions, and a QR code.*

FDA Label Image

Figure 1: Effect Of Interacting Drugs On The Pharmacokinetics Of Venlafaxine And Active Metabolite O-desmethylvenlafaxine (odv). (Venlafaxine Fig1)

Pharmacokinetic fold change graph showing the effect of various interacting drugs on venlafaxine's Cmax and AUC, along with ODV metabolite changes. The chart includes recommendations for concomitant use, such as dose adjustments or cautions, relative to the reference value.*

FDA Label Image

Figure 2: Effect Of Venlafaxine On The Pharmacokinetics Interacting Drugs And Their Active Metabolites. (Venlafaxine Fig2)

A pharmacokinetic (PK) fold change chart showing the impact of various interacting drugs on the Cmax and AUC of Venlafaxine Hydrochloride. It lists interacting drugs on the left, with corresponding analytes and PK changes plotted against a reference value on the x-axis. Recommendations regarding dose adjustments or clinical significance are provided on the right.*

FDA Label Image

Figure 3: Pharmacokinetics Of Venlafaxine And Its Metabolite O-desmethylvenlafaxine (odv) In Special Populations. (Venlafaxine Fig3)

A clinical pharmacokinetic chart displaying fold changes and 90% confidence intervals for venlafaxine hydrochloride exposure (Cmax, AUC) under various special populations including hepatic (cirrhosis, mild, moderate impairment), renal (mild/moderate impairment, hemodialysis), CYP2D6 polymorphism status, age over 60 years, and gender. The chart includes dosing recommendations based on these pharmacokinetic changes.*

FDA Label Image

Chemical Structure (Venlafaxine Str)

Chemical structure of venlafaxine hydrochloride, showing the molecular arrangement of atoms including a dimethylamino group, cyclohexane ring, and methoxy-substituted phenyl ring with associated hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.